Patent: 8,445,190
✉ Email this page to a colleague
Summary for Patent: 8,445,190
Title: | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
Abstract: | Methods for reducing or eliminating biomaterial-induced procoagulant activity in blood subjected to extracorporeal treatment that exposes the blood to the biomaterial are disclosed. The methods involve treatment of the blood, or the extracorporeal biomaterial, or both, with a complement inhibitor to inhibit C5a/C5aR-mediated tissue factor formation in the blood. |
Inventor(s): | Lambris; John D. (Philadelphia, PA), Ritis; Konstantinos (Alexandroupolis, GR) |
Assignee: | The Trustees of the University of Pennsylvania (Philadelphia, PA) |
Application Number: | 13/121,396 |
Patent Claims: | see list of patent claims |
Details for Patent 8,445,190
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Alexion Pharmaceuticals, Inc. | SOLIRIS | eculizumab | Injection | 125166 | 03/16/2007 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |